Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting…
Consensus price target: $7.00 (+134.11% upside from $2.99)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2026 | $1.17M | -92.5% | $-13.45M |
| 2025 | $15.65M | — | $-369.63K |
| 2024 | $0 | — | $-15.49M |
Stock data for NEUP: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics